Full Press Release Details
DUBLIN , Oct. 21, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its 2014 third quarter financial results on Tuesday, November 4, 2014 , after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST / 9:30 p.m. GMT to provide a business and financial update and discuss third quarter 2014 financial results.
Interested parties may access the live audio webcast via the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com . Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for one week.
Audio webcast/conference call: U.S. Dial-In Number: +1 866 318 8615 International Dial-In Number: +1 617 399 5134 Passcode: 57934182
A replay of the conference call will be available through November 11, 2014 and accessible through one of the following telephone numbers and entering the passcode:
Replay U.S. Dial-In Number: +1 888 286 8010 Replay International Dial-In Number: +1 617 801 6888 Passcode: 24997214
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. The company has a diverse portfolio of products and/or product candidates in the areas of sleep, hematology/oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi ), Prialt® (ziconotide) intrathecal infusion, Versacloz® (clozapine) oral suspension, FazaClo® (clozapine, USP) HD and FazaClo LD. Jazz Pharmaceuticals also has a number of products marketed outside the U.S., including Erwinase® and Defitelio® (defibrotide). For more information, please visit www.jazzpharmaceuticals.com .
To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2014-third-quarter-financial-results-on-november-4-2014-532521933.html
SOURCE Jazz Pharmaceuticals plc